Conclusion

These exciting new developments hold promise for a host of challenging medical conditions. We eagerly await the outcomes of clinical trials and further reports on the efficacy of new agents.

References


Continue Reading

1.  Ebinger M, Kunz A, Wendt M, et al. Effects of Golden Hour Thrombolysis: A Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) Substudy. JAMA Neurol. 2014 Nov 17. [Epub ahead of print]

2. Ebinger M, Winter B, Wendt M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA. 2014 Apr 23-30;311(16):1622-31.

3. World Health Organization (WHO). Dengue. (2014) http://www.who.int/denguecontrol/en/. Accessed: November 20, 2014.

4. Jindal H, Bhatt B, Malik JS, Sk S. Dengue vaccine. Hum Vaccin Immunother. 2014 Aug;10(8):2245-6.

5. Thomas SJ. Preventing Dengue – Is the Possibility Now a Reality? N Engl J Med. 2014 Nov 3. [Epub ahead of print]

6. Cleveland Clinic. Cleveland Clinic Unveils Top 10 Medical Innovations for 2015. http://my.clevelandclinic.org/about-cleveland-clinic/newsroom/releases-videos-newsletters/cleveland-clinic-unveils-top-10-medical-innovations-for-2015/ Accessed: November 20, 2014.

7. Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug

conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57(16):6949-64.

8. Wang DH, Guo L, Wu XH. Checkpoint inhibitors in immunotherapy of ovarian cancer. Tumour Biol. 2014 Nov 20. [Epub ahead of print]

9. Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res. 2014;6:63-75.

10. Siu, LL. Delivering precision immunotherapy. European Society for Medical Oncology, Barcelona, Spain. Presented September 27, 2014.

11. Lee KL. In the wireless era: leadless pacing. Expert Rev Cardiovasc Ther. 2010;8(2):171-4.

12. Reddy VY, Knops RE, Sperzel J, et al.  Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation. 2014;129(14):1466-71.

13. United States Food and Drug Administration. FDA approves Esbriet to treat idiopathic pulmonary fibrosis. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm. Accessed: November 25, 2014.

14. Covvey JR, Mancl EE. Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. Ann Pharmacother. 2014;48(12):1611-1619.

15. Bitterman A, Shiloni E, Goldman I, et al. Intraoperative radiotherapy (IORT) in early breast cancer. Harefuah. 2014;153(8):460-2, 498.

16. Sedlmayer F, Reitsamer R, Fussl C, et al. Boost IORT in Breast Cancer: Body of Evidence. Int J Breast Cancer. 2014;2014:472516.

17. von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther. 2014 Oct;144(1):41-9.

18. Packer M, McMurray JJ, Desai AS, et al.  Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation. 2014 Nov 17. [Epub ahead of print]

19. Ascend Pharmaceuticals. AAP-002. http://www.ascendbiopharma.com/philosophy/asn-002/. Accessed: December 2, 2014.

20. Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014;15(18): 2629-39.

21. Mancini D, CUPID Trial Investigators. Sustained improvement in clinical outcomes with MYDICAR compared to optimal therapy 1-year after initial gene therapy in patients with advanced heart failure—the CUPID trial. Circulation. 2010; 122: A19470.